This position is responsible to perform physiochemical and microbiological tests according to written validation protocols. Interpret results, complete and review laboratory data, and submit records for final approval.

Main Responsibilities & Tasks:

Provide qualification/validation quality/compliance support comply with laboratory safety procedures and requirements of Sartorius.
Perform validation study for single use systems, filter elements tests according to SOPs and approved validation protocols.
Performing in-coming material testing.
Prepare and handle test solutions, chemicals and reagents necessary according to government regulations and company SOPs for the performance of all laboratory tests.
Inform lab manager of any deviations related to validation protocol execution.
Initiate and complete any investigations related to deviation of validation protocols or out of specification results.
Perform necessary cleaning and sanitizing of the lab and equipment after testing to keep the lab tidy.
Perform inventory control of consumables, standard reagents to ensure the safety stock.
Perform qualification, calibration and maintenance of relevant equipment or device.
Assists project management (feasibility check of validation studies).
Assists in maintenance of Standard Operating Procedures, incl. writing and revising.
Other tasks assigned by lab manager.

Qualifications & Skills:

Bachelor degree in Sciences/Engineering or Technical Science/Technological degree
2-3 years’ work experience for chemical analysis
Experience in the pharmaceutical industry is a plus
Good understanding of GMP requirements
Good knowledge of Microsoft Office Applications
Detail oriented personality
Good communication skills
Team and customer service orientated attitude
Ability to analyze and solve problems

About Sartorius

Sartorius is part of the solution in the fight against cancer, dementia, and many other diseases. Our technologies help translate scientific discoveries into real-world medicine faster, so that new therapeutics can reach patients worldwide.

We look for ambitious team players and creative minds, who want to contribute to this goal and advance their careers in a dynamic global environment.

Join our global team and become part of the solution. We are looking forward to receiving your application.
www.sartorius.com/careers

About the company

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify's Take

What believers are saying

H1 2026 operational sales rose 7.7%, and management reaffirmed full-year guidance.
May 2026 bond refinancing lowered funding pressure before the €650 million maturity.
ElevateBio pilot validation and September 2026 ordering support Eveo sales conversion in 2027.

What critics are saying

Tariff refunds and customer compensation cut 2026 revenue by up to €35 million.
Lab Products grew only 5.3% operationally in H1 2026, lagging Bioprocess Solutions.
Delayed advanced-therapy orders from two customers shift revenue into 2027, hurting execution confidence.

What makes Sartorius unique

Eveo launches March 16, 2026, integrating cell therapy manufacturing and QC in one system.
Bioprocess Solutions dominates with high-recurring consumables and switching costs across biologics manufacturing.
Stedim Biotech integration gives Sartorius tighter control over single-use bioprocessing and global customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget

Company News

Yahoo Finance

Oct 23rd, 2026

Sartorius Stedim Biotech nine-month sales up 7.8% to $2.5B, full-year guidance confirmed

Sartorius Stedim Biotech reported nine-month sales growth of 7.8% in constant currencies, or 6.5% after tariff-related customer compensation. Sales reached €2.29 billion, driven by strong consumables and a recovering equipment business. Underlying EBITDA rose 4.8% to €716 million, with a margin of 31.3%. Underlying net profit climbed 9.4% to €350 million, and free cash flow jumped 58.5% to €264 million. Net debt stood at €2.14 billion, or 2.26 times underlying EBITDA. Americas growth lagged at 3.9% including tariff compensation, hurt by project delays in Advanced Therapies. The company confirmed full-year guidance: operational sales growth near the midpoint of 6% to 10% and an underlying EBITDA margin slightly above 31%.

Yahoo Finance

Jul 23rd, 2026

Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS

May 15th, 2026

Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG

May 6th, 2026

Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius